Medical Radiology and Radiation Safety. 2026. Vol. 71. № 6

DOI:10.33266/1024-6177-2026-71-6-7-18

Yu.D. Udalov, M.V. Vasin, I.B. Ushakov

COMPARATIVE RADIOPROTECTIVE EFFICACY OF RADIOPROTECTANTS IN ANIMAL EXPERIMENT AND ITS EXTRAPOLATION TO HUMANS

A.I. Burnazyan Federal Medical Biophysical Center, Moscow, Russia

Contact person: M.V. Vasin, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.  

СONTENT

The presented review considers the current state of the comparative assessment radioprotective properties of the most active known radioprotective agents: among radioprotectors. Particular attention is focused on the protective activity of radioprotectors in large animals (dogs), as an important and necessary stage for extrapolating experimental data to humans. In  DRF his series, in experiments on dogs, the first place is occupied by indralin with  a  dose reduction factor equal to 3 ( DRF = 3), then amifostine with a DRF = 2.5, cystamine and naphthysine with a DRF = 1.5. When tested in radiotherapy of cancer patients, the DRF of amifostine and phenylephrine was 1.4. The only radioprotector that has radioprotective properties when used orally was indralin with DRF up to 1.5.

The second question is related to the justification of new approaches to the indication of the radioprotective properties of indralin by physiological parameters of its effect on the human. It was found that circulatory hypoxia due to the vasoconstrictor effect of indralin as an alpha1-adrenergic agonist is able to reduce oxygen tension in the bone marrow to 50% is not able by itself provide radiation protection in experiments on dogs, which is important in humans. For this reason, the change in blood pressure under the influence of indralin as the simplest and most affordable method for assessing the effect of the radioprotector on a person cannot radically add to the increase in the accuracy of predicting the effectiveness of indralin in humans carried out taking into account the rate of metabolism of the radioprotector when comparing the effect of the drug with equal concentrations in the blood of animals and humans, which was calculated to have its IM administration ED50 equal to 100 mg (1.4‒1.5 mg/kg).

Our further studies were devoted to a comparative analysis of the manifestation of acute hypoxia with the use of indralin in small and large animals and humans on the development of acute stress recorded by SDH activation of blood lymphocytes under the influence of adrenaline release into the blood. It was found that there was a 4-fold increase in adrenoreactivity along the mouse-dog-human evolutionary ladder for acute cytotoxic hypoxia when indralin was administered at the dog-human site. Based on this fact, it was found that the human dose of indralin 100 mg IM corresponds to the acute stress level of 10 mg/kg in dogs, whose radioprotective properties are equal in DRF = 2. Based on a comparison of equal doses close to ED50, parenteral and oral administration of indralin in experiments in dogs revealed a difference between them by 4‒5 times. If the same difference between the doses of the drug is adopted in these methods of using the radioprotector in humans, then its dose of 0.45 g orally will be equal to the effect of 100 mg IM. This relationship is confirmed when comparing the pharmacodynamics of indralin in humans by the change in blood pressure during its parenteral and oral use. Taking into account that when indralin was administered orally to dogs, radioprotective effect of indralin in experiments on dogs did not exceed 1.5 in terms of DRF, it can be taken as a working hypothesis that the dose of 0.45 g of indralin for humans when used orally has radiation protection properties equal to 1.5 in terms of DRF.

Keywords: indralin, amifostine, extrapolation of protective properties of radioprotectants to humans, circulatory hypoxia, tissue hypoxia, blood lymphocyte SDH

For citation:  Udalov YuD, Vasin MV, Ushakov IB. Comparative Radioprotective Efficacy of Radioprotectants in Animal Experiment and its Extrapolation to Humans. Medical Radiology and Radiation Safety. 2026;71(6):7–18. DOI:10.33266/1024-6177-2026-71-6-7-18

 

References

1. Saksonov P.P., Shashkov V.S., Sergeyev P.V. Radiatsionnaya Farmakologiya = Radiation Pharmacology. Moscow, Meditsina Publ., l976. 255 p. (In Russ.).

2. Singh V.K., Romaine P.L.P., Seed T. M. Medical Countermeasures for Radiation Exposure and Related Injuries Characterization of Medicines, FDA-Approval Status and Inclusion into the Strategic National Stockpile. Health Physics 2015;108;6:607-630. Doi: 10.1097/HP.0000000000000279.

3. Mishra K., Alsbeih G., Appraisal of Biochemical Classes of Radioprotectors: Evidence, Current Status and Guidelines for Future Development. Biotech. 2017;7;5:292. Doi: 10.1007/s13205-017-0925-0.

4. Obrador E., Salvador R., Villaescusa J.I., et al. Radioprotection and Radiomitigation: From the Bench to Clinical Practice. Biomedicines. 2020;8;11:461.  Doi: 10.3390/biomedicines8110461. 

5. Palkar P.A., John G., Chekuri G., et al. Radioprotectors & Mitigators in Radiation Therapy: Harnessing Diverse Pathways for Optimizing Clinical Outcomes. Indian J. Med. Res. 2025;162;3:343-366. Doi: 10.25259/IJMR_542_2025.

6. Koukourakis M.I., Kyrias G., Kakolyris S., et al. Subcutaneous Administration of Amifostine during Fractionated Radiotherapy: a Randomized Phase II Study. J. Clin. Oncol. 2000;18;11:2226-33. Doi: 10.1200/JCO.2000.18.11.2226.

7. Vasin M.V., Chernov Yu.N., Semenova L.A. Anti-Radiation Properties of Radioprotectors, Immunomodulators and Agents Affecting Tissue Metabolism during Fractionated Irradiation. Radiobiologiya = Radiobiology. 1991;31;2:271–275 (In Russ.).

8. Zois C.E., Giatromanolaki A., Sivridis E., et al. Narrow Amifostine Dose Windows Define Radioprotection Outcome, Following Fractionated Whole-Body Irradiation of Mice. In Vivo. 2011;25;2:191-196. 

9. Vasin M.V., Ushakov I.B., Chernov Yu.N., et al. Radiation Protection Properties of Indralin and Essentiale N when Used Separately and in Combination Under Conditions of Fractionated γ-Irradiation. Radiatsionnaya Biologiya. Radioekologiya = Radiation Biology. Radioecology. 2021;61;6:645–651 (In Russ.).

10. Bacq Z.M., Неrvе А., Lecomte J., et al. Protection Contre le Rayonnement X par la Beta-Mercaptoethylamine. Аrсh. Int. Physiol. l95l;59;4:442-447.

11. Stone H.B., Moulder J.E., Coleman C.N., et al. Models for Evaluating Agents Intended for the Prophylaxis, Mitigation and Treatment of Radiation Injuries. Radiat. Res. 2004;162:711–728.

12. Vasin M.V. Classification of Means for the Prevention of Radiation Injuries as the Formation of a Conceptual Basis for Modern Radiation Pharmacology. Radiatsionnaya Biologiya. Radioekologiya = Radiation Biology. Radioecology. l999;39;2-3:212-222 (In Russ.).

13. Vasin M.V. The Non‐Uniformity of the Absorption of Ionizing Radiation Energy in the Body Potentiates the Radioprotective Effects of Drugs: Influence on the Post‐Radiation Recovery of Radiosensitive Tissues with High‐Dose Total‐Body Irradiation. Med. Hypotheses Res. 2012;8:39–49.

14. Vasin M.V. Classification of Radiation Protection Agents as a Reflection of the Current State and Prospects for the Development of Radiation Pharmacology. Radiatsionnaya Biologiya. Radioekologiya = Radiation Biology. Radioecology. 2013;53;5:459–467 (In Russ.).

15. Vasin M.V. Comments on the Mechanisms of Action of Radiation Protective Agents: Basis Components and Their Polyvalence. Springer Plus. 2014;3:414. URL: http://www.springerplus.com/content/3/1/414.

16. Vasin M.V. Protivoluchevyye Lekarstvennyye Sredstva = Radiation Protection Drugs. Moscow, Kniga-Memuar Publ., 2020. 238 p. (In Russ.). 

17. Vasin M.V., Antipov V.V., Suvorov N.N., et al. Radioprotective Properties of Idolylalkylaminoethanols. Radiobiologiya = Radiobiology. 1971;11;5:779-781 (In Russ.).

18. Instructions for Medical Use of B-190 (150 mg Tablets). RU No. LP (008789)-(RG-RU) dated October 21, 2021 (In Russ.).

19. Il’in L.A., Rudnyy N.M., Suvorov N.N., et al. Indralin – Radioprotektor Ekstrennogo Deystviya: Protivoluchevyye Svoystva, Farmakologiya, Mekhanizm Deystviya, Klinika = Indralin – an Emergency-Action Radioprotector: Radiation Protection Properties, Pharmacology, Mechanism of Action, Clinical Features. Moscow, Ministry of Health of the Russian Federation Publ., 1994. 435 p. (In Russ.).

20. Romodin L.A., Nikitenko O.V., Bychkova T.M., et al. Comparative Evaluation of the Radiation-Protective Properties of Copper Chlorophyllin, Trolox, and Indralin in Experiments on Mice. Byulleten’ Eksperimental’noy Biologicheskoy Meditsiny = Bulletin of Experimental Biological Medicine. 2014;177;3:328-332 (In Russ.).

21. Vasin M.V., Antipov V.V., Chernov G.A., et al. Study of the Radioprotective Effect of Indralin on the Hematopoietic System in Various Animal Species. Radiatsionnaya Biologiya. Radioekologiya = Radiation Biology. Radioecology. 1996;36;2:168-189 (In Russ.).

22. Vasin M.V., Ushakov I.B., Suvorov N.N. Radiation Protection Efficacy of Indralin during Local γ-Irradiation of the Skin. Radiatsionnaya Biologiya. Radioekologiya = Radiation Biology. Radioecology. 1998;38;1:42–54 (In Russ.).

23. Vasin M.V., Ushakov I.B., Kovtun V.Yu. Radioprotector Indralin in Early and Late Manifestations of Local Radiation Injuries. Voprosy Onkologii = Problems in Oncology. 2016;62;3:406–412 (In Russ.).

24. Vasin M.V., Ushakov I.B., Korovkina E.P., Kovtun V.Yu. Radiation Protection Properties of Indralin in Reducing the Severity of Radiation Injury to the Salivary Glands. Radiatsionnaya Biologiya. Radioekologiya = Radiation Biology. Radioecology. 2004;44;3:333–335 (In Russ.).

25. Vasin M.V., Ushakov I.B., Semenova L.A., et al. Radiation Protection Efficacy of α1-Adrenergic Agonists during Local γ-Irradiation of the Skin. Radiatsionnaya Biologiya. Radioekologiya = Radiation Biology. Radioecology. 1999;39;2-3:249–253 (In Russ.).

26. Vasin M.V., Il’in L.A., Ushakov I.B. The Phenomenon of Radiation Protection by Indralin in Large Animals (Dogs) and its Extrapolation to Humans. Meditsinskaya Radiologiya. Radiatsionnaya Bezopasnost’ = Medical Radiology. Radiation Safety. 2022;67;3:5–12 (In Russ.). Doi: 10.33266/1024-6177-2022-67-3-5-12.

27. Vasin M.V., Semenov L.F., Suvorov N.N., et al. Protective Effect and the Therapeutic Index of Indralin in Juvenile Rhesus Monkeys. J. Radiat. Res. 2014;55:1048-1055. Doi: 10.1093/jrr/rru046.

28. Singh V.K., Seed T.M. The Efficacy and Safety of Amifostine for the Acute Radiation Syndrome. Expert Opinion Drug Safety. 2019;18;11:1077-1090. Doi: 10.1080/14740338.2019.1666104.

29. Yuhas J.M., Storer J.B. Chemoprotection Against Three Modes of Radiation Death in the Mouse. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 1969;15:233–237.

30. Rasey J.S., Nelson N.J., Mahler P., et al. Radioprotection of Normal Tissues Against Gamma Rays and Cyclotron Neutrons with WR-2721: LD50 Studies and 35S-WR-2721 Biodistribution. Radiat Res. 1984;97:598–607.

31. Brown D.Q., Pittock J.W. 3rd, Rubinstein J.S. Early Results of the Screening Program for Radioprotectors. Int. J. Radiat. Oncol. Biol. Phys. 1982;8:565–570.

32. Kuna P. Duration and Degree of Radioprotection of WR-2721 in Mice Following its Intraperitoneal, Intramuscular and Subcutaneous Administration. Radiobiol Radiother (Berl). 1983;24:357–364.

33. Vygodskaya A.L., Yarmonenko S.P. Efficiency of Gammaphos during Irradiation Under Conditions of Normal Oxygenation and Hypoxia. Meditsinskaya Radiologiya = Medical Radiology. 1984;29;8:38-43 (In Russ.).

34. Terekhov A.V., Besedina L.N., Zherebchenko P.G., et al. Toxicity and Radiation Protection Activity of Aminopropylaminoethylthiophosphate. Radiobiologiya = Radiobiology. 1976;16;2:249-252 (In Russ.).

35. Travis E.L., Fang M.Z., Basic I. Protection of Mouse Bone Marrow by WR2721 after Fractionated Irradiation. Int. J. Radat. Oncol. Biol. Phys. 1988;15:377-382.

36. Ito H., Meistrich M.L., Barkley H.T. Jr., et al. Protection of Acute and Late Radiation Damage of the Gastrointestinal Tract by WR2721. Int. J. Radiat. Oncol. Biol. Phys.1986;12:211-219

37. Lowy R.O., Baker D.G. Protection Against Local Irradiation Injury to the Skin by Locally and Systemically Applied Drugs. Radiobiology. 1972;105;2:425-428. Doi: 10.1148/105.2.425.

38. Stewart F.A., Roias A. Protection of Mouse Skin by WR2721 in Single and Fractionated Treatments. Br. J. Radiol. 1982;55:42-47

39. Menard T.W., Isutsu K.T., Ensign W.Y., et al. Radioprotection by WR2721 of Gamma-Irradiated Rat Parotid Gland Effect on Gland Weight and Secretion at 8-10 Days Post Irradiation. Int. J. Radiat. Oncol. 1984;10:1555-1559.

40. Trog D., Bank P., Wendt T.G., et al. Daily Amifostine Given Concomitantly to Chemoradiation in Head and Neck Cancer. A Pilot Study. Strahlentherapie Oncol. 1999;175;9:444-449. 

41. Vasin M.V., Saksonov P.P., Antipov V.V., Shashkov V.S. Antiradiation Activity of Aminothiols and Dependence on the Dose and Duration of its Use Under Various Irradiation Conditions. Radiobiologiya = Radiobiology. 1970;10;3:380-385 (In Russ.).

42. Krasil’nikov I.I. Radiozashchitnoye Sredstvo = Radioprotective Agent. Patent RU2144357C1. St. Petersburg, Nauchno Isledovatel’skiy Institut Voyennoy Meditsiny Publ., 20.01.2000 (In Russ.).

43. Soref C.M., Fahl W.E. A New Topical Vasoconstrictor-Based Strategy for Prevention of Oral Mucositis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2014;117;4:454-61. Doi: 10.1016/j.oooo.2013.12.005. 

44. Cleary J.F., Anderson B.M., Jens C Eickhoff J.C., et al. Significant Suppression of Radiation Dermatitis in Breast Cancer Patients Using a Topically Applied Adrenergic Vasoconstrictor. Radiat Oncol. 2017;12;1:201. Doi: 10.1186/s13014-017-0940-7.

45. Graul-Conroy A.,  Hoover-Regan M.,  DeSantes K.B., et al. Reduction in Oral Mucositis Severity Using a Topical Vasoconstrictor: A Case Report of Three Bone Marrow Transplant Patients. Integr. Cancer Sci. Ther. 2018;5;6:10.15761/ICST.1000293.  Doi: 10.15761/ICST.1000293. 

46. Vasin M.V. Drug B-190 (Indralin) in Light of the History of the Formation of Concepts on the Mechanism of Action of Radioprotectors. Radiatsionnaya Biologiya. Radioekologiya = Radiation Biology. Radioecology. 2020;60;4:378–395 (In Russ.).

47. Vasin M.V., Chernov G.A., Antipov V.V. The Breadth of the Radioprotective Effect of Indralin in Comparative Studies on Various Animal Species. Radiatsionnaya Biologiya. Radioekologiya = Radiation Biology. Radioecology. 1997;37;6:896–904 (In Russ.).

48. Voytkevich N.D., Palyga G.F. Radiation Protection Efficiency of Mexamine. Meditsinskaya Radiologiya = Medical Radiology. 1974;19;1:74–86 (In Russ.).

49. Vasin M.V., Davydov B.I., Antipov V.V. Comparative Elimination of the Radioprotective and Toxic Effect of Cystamine. Radiobiologiya = Radiobiology. 1971;11;4:517-521 (In Russ.).

50. Palmer T.E.,  Glaza S.M., Dickie B.C., et al. Toxicity Studies on the Radioprotective Agent WR-2721 in CDF1 Mice and Beagle Dogs. Toxicol. Pathol. 1985;13;1:58-65. Doi: 10.1177/019262338501300108.

51. Wagner M., Sedlmeier H., Metzger E., et al. Untersuchungen zu Toxizität und Strahlenschutz Effect der Chemischen Strahlenschutzsubstanz WR-2721 Bei Beagle-Hunden. Teil II: Strahlenschutzeffekt des WR-2721. Strahlentherapie. 1980;156;9:655-662.

52. Wagner M., Sedlmeier H., Wustrow T., et al. Untersuchungen zu Toxizität und Strahlenschutz Effect der Chemischen Strahlenschutzsubstanz WR-2721 Bei Beagle-Hunden. Teil I: Toxizität des WR-2721. Strahlentherapie. 1980;156;7:486-491.

53. Vasin M.V., Ushakov I.B., Kovtun V.YU., Semenova L.A., Komarova S.N. The Influence of Melatonin, Ascorbic and Succinic Acids on the Cumulation of the Toxic Effect of Gammaphos (Amifostine) during its Repeated Use. Byulleten’ Eksperimental’noy Biologicheskoy Meditsiny = Bulletin of Experimental Biology and Medicine. 2004;137;5:515–518 (In Russ.).

54. Turrisi A.T., Kligerman S., Glover J., et al. I Phase of Clinical Investigation of WR-2721. Radioprotectors and Cancirogens. Ed. Negaard P.F. New York, Ac. Press, 1983. P. 681-694.

55. Lu Z. Optimization of Amifostine Administration for Radioprotection. Doctor’s Thesis (Ph.). Michigan, University of Michigan, 2007. 143 p.

56. Сzerwinski A.W., Clark M.L. Report MCA 1-33. Fort Detrick, U.S. Army Med. Res. Develop. Command, 1972.

57. Shekunova Ye.V., Kovaleva M.A., Makarova M.N. Makarov V.G. Selecting a Drug Dose for Preclinical Studies: Interspecies Dose Transfer. Vedomosti Nauchnogo Tsentra Ekspertizy Sredstv Meditsinskogo Primeneniya = The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2020;10;1:10-28 (In Russ.).

58. Vasin M.V., Antipov V.V., Chernov G.A., et al. The Role of the Vasoconstrictor Effect in the Implementation of the Radiation-Protective Properties of Indralin in Experiments on Dogs. Radiatsionnaya Biologiya. Radioekologiya = Radiation Biology. Radioecology. 1997;37;1:46-55 (In Russ.).

59. Vasin M.V., Ushakov I.B., Koroleva L.V., Antipov V.V. The Role of Cellular Hypoxia in the Radiation-Protective Effect of Radioprotectors. Radiatsionnaya Biologiya. Radioekologiya = Radiation Biology. Radioecology. 1999;39;2–3:238–248 (In Russ.).

60. Udalov Yu.D. Gipoksiya v Razvitii Fatal’nykh Oslozhneniy u Patsiyentov Onkokhirurgicheskogo Profilya = Hypoxia in the Development of Fatal Complications in Patients with Oncosurgical Profile. Moscow, FMBTS im. A.I. FMBA Rossii Publ., 2019. 252 p. (In Russ.).

61.Antipov V.V., Vasin M.V., Gaydamakin A.N. Species Features of the Response of SDH Lymphocytes in Animals to Acute Hypoxic Hypoxia and its Relationship with the Radioresistance of the Organism. Kosmicheskaya Biologiya. Aviakosmicheskaya Meditsina = Space Biology. Aerospace Medicine. 1989;23;2:63–66 (In Russ.).

62. Doherty J.R. The Pharmacology of α1-Adrenoceptor Subtype. Eur. J. Pharmacol. 2019;855:305-320. Doi: 10.1016/j.ejphar.2019.04.047. 

63. Perez D.M. Current Developments on the Role of α1-Adrenergic Receptors in Cognition, Cardioprotection, and Metabolism. Front. Cell Dev. Biol. 2021;9:652152. Doi: 10.3389/fcell.2021.652152.

64. Vasin M.V., Ushakov I.B. Potential Role of Participation of the Adaptive Response of the Cellular Sensor of Bioenergetic Processes AMP-Activated Protein Kinase in the Action of Alpha-Adrenergic Agonist Radioprotectors. Radiatsionnaya Biologiya. Radioekologiya = Radiation Biology. Radioecology. 2024;64;1:10-20 (In Russ.). Doi: 10.31857/S0869803124010022.

65. Udalov Yu.D., Danilova L.A., Udalova M.A., Tikhomirov N.Ye. Use of Proton Beam Therapy and Nuclear Medicine Methods in the Federal Scientific Center of Radiology and Oncology of the Federal Medical and Biological Agency: Results and Prospects. Voprosy Onkologii = Problems in Oncology. 2023;69;3S:425-426 (In Russ.).

66. Vasin M.V., Ushakov I.B., Kovtun V.Yu. Radioprotector Indralin in Early and Late Manifestations of Local Radiation Injuries. Voprosy Onkologii = Problems in Oncology. 2016;62;3:406-412 (In Russ.).

67. Vasin M.V., Yermakova N.P., Krimker V.M. Adrenergic Agonists as a Component of Polyradiomodification in Tumor Radiation Therapy. Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost’ = Medical Radiology and Radiation Safety. 2011;56;1:5-10 (In Russ.).

68. Fahl W.E. Effect of Topical Vasoconstrictor Exposure Upon Tumoricidal Radiotherapy. Int. J. Camcer. 2014;135;4:981-988. Doi: 10.1002/Ijc.28739.

69. Soref C.M.,  Fahl W.E. A New Topical Vasoconstrictor-Based Strategy for Prevention of Oral Mucositis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2014;117;4:454-61. Doi: 10.1016/j.oooo.2013.12.005. 

70. Cleary J.F.,  Anderson B.M., Jens C Eickhoff J.C., et al. Significant Suppression of Radiation Dermatitis in Breast Cancer Patients Using a Topically Applied Adrenergic Vasoconstrictor. Radiat Oncol. 2017;12;1:201. Doi: 10.1186/s13014-017-0940-7.

71. Graul-Conroy A.,  Hoover-Regan M.,  DeSantes K.B., et al. Reduction in Oral Mucositis Severity Using a Topical Vasoconstrictor: a Case Report of Three Bone Marrow Transplant Patients. Integr. Cancer Sci. Ther. 2018;5;.6.  Doi: 10.15761/ICST.1000293. 

72. Norris W.P., Fritz T.E., Rehfeld C.E., Poole G.M. Response of Reagle Dog to Cobalt-60 Gamma-Radiation. Determination of the LD50 and Description of Associated Changes. Radiat. Res. 1968;35:681-708.

73. MacVittie T.J., Monroy R., Vigmeulle R.M., et al. The Relative Biological Effectiveness of Fission-Neutron-Gamma Radiation on Hematopoietic Syndrome in the Canine: Effect of Therapy on Survival. Radiat. Res. 1991;128;1:S29-S36.

74. MacVittie T.J., Jackson W. Acute Radiation-Induced GI-ARS and H-ARS in a Canine Model of Mixed Neutron/Gamma Relative to Reference Co-60 Gamma Radiation: A Retrospective Study. Health Phys. 2020;119;3:351-357. Doi: 10.1097/HP.0000000000001215.

 

 PDF (RUS) Full-text article (in Russian)

 

Conflict of interest.The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors.

Article received: 20.06.2026. Accepted for publication: 25.07.2026.